Influenza Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
Description
The global influenza diagnostics market is projected to grow significantly over the forecast period from 2025 to 2032. As the burden of seasonal influenza continues to rise globally, the need for rapid, accurate, and accessible diagnostic testing is increasing. The market is forecast to expand from USD 2 billion in 2025 to USD 3.3 billion by 2032, reflecting a strong compound annual growth rate (CAGR) of 7.42%.
Market Insights
The influenza diagnostics Analysis has evolved with the integration of advanced molecular testing technologies. Diagnostic methods such as real-time RT-PCR, nucleic acid amplification, and rapid antigen detection have become integral tools in clinical and point-of-care settings. These innovations have enabled faster turnaround times, improved diagnostic accuracy, and enhanced management of influenza outbreaks.
The increased adoption of point-of-care tests and CLIA-waived molecular assays is transforming how influenza is diagnosed, enabling broader access to early detection, especially in decentralized and outpatient settings.
Market Drivers
The market is being fueled by several key factors. Chief among them is the rising global incidence of influenza, which continues to strain public health systems and drive demand for early detection solutions. Rapid technological progress in diagnostic platforms—especially in molecular diagnostics—has made it possible to detect influenza viruses with higher precision and speed.
Government and institutional support for R&D initiatives further supports the market’s growth trajectory. Initiatives such as the Vaccine and Therapy Evaluation Units (VTEUs) and the CIVICs program have injected substantial funding into the development of next-generation diagnostic tools and flu surveillance systems.
Business Opportunity
The shift toward decentralized testing and the growing availability of portable, user-friendly diagnostic kits present major growth opportunities for market participants. Manufacturers are increasingly focusing on delivering cost-effective molecular solutions suitable for resource-constrained settings, including emerging markets.
At the same time, the increasing demand for diagnostics in outpatient clinics, urgent care centers, and pharmacies highlights the need for scalable, easy-to-use platforms that require minimal technical expertise. This trend is opening doors for innovation in home-based and self-administered flu testing solutions.
Regional Analysis
North America remains the largest regional market, with the U.S. accounting for a dominant share due to the high prevalence of influenza, robust healthcare infrastructure, and the strong presence of diagnostic companies. The country continues to invest in advanced testing technologies, supporting rapid product development and commercialization.
Germany leads the European market owing to a combination of government support, presence of diagnostic manufacturers, and high awareness around influenza prevention and early detection. New kit launches and strategic collaborations among key players are driving innovation in the country.
In East Asia, Japan emerges as a key market, supported by a technologically advanced healthcare system, rising incidence of flu infections, and a growing geriatric population. Regulatory support and favorable insurance policies further facilitate access to advanced diagnostics.
Key Growth Drivers
The competitive Analysis is marked by strategic mergers, acquisitions, and product expansions. Key players are focusing on strengthening their product offerings and entering untapped regional markets.
• Thermo Fisher Scientific has introduced user-friendly RT-PCR systems such as QuantStudio 3 and 5, enabling remote access and analysis.
• Quidel Corporation has expanded its portfolio with FDA-cleared rapid flu and COVID-19 combo tests.
• Roche’s acquisition of GenMark Diagnostics has bolstered its molecular diagnostics capabilities, enhancing its global presence.
Other major players include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux Inc., Danaher Corporation (Cepheid), GenMark Diagnostics, Luminex Corporation, Meridian Bioscience, Inc., and Hologic.
Market Segmentation
By Test Type:
• Molecular Diagnostic Tests
RT-PCR
LAMP
NASABA
• Traditional Diagnostic Tests
Rapid Influenza Detection Test
Serological Assays
Direct Fluorescent Antibody
Viral Culture
H1N1 Influenza A Virus Identification Kits
Immunoassay Kits
Immunofluorescence Antibody Assay
By Type of Flu:
• Type A Flu
• Type B Flu
• Type C Flu
By End User:
• Hospitals
• Diagnostic Laboratories
• Research & Academic Institutes
• Contract Research Organizations (CROs)
By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Oceania
• Middle East & Africa
Please note: Delivery Timelines - 5 working days.
Market Insights
The influenza diagnostics Analysis has evolved with the integration of advanced molecular testing technologies. Diagnostic methods such as real-time RT-PCR, nucleic acid amplification, and rapid antigen detection have become integral tools in clinical and point-of-care settings. These innovations have enabled faster turnaround times, improved diagnostic accuracy, and enhanced management of influenza outbreaks.
The increased adoption of point-of-care tests and CLIA-waived molecular assays is transforming how influenza is diagnosed, enabling broader access to early detection, especially in decentralized and outpatient settings.
Market Drivers
The market is being fueled by several key factors. Chief among them is the rising global incidence of influenza, which continues to strain public health systems and drive demand for early detection solutions. Rapid technological progress in diagnostic platforms—especially in molecular diagnostics—has made it possible to detect influenza viruses with higher precision and speed.
Government and institutional support for R&D initiatives further supports the market’s growth trajectory. Initiatives such as the Vaccine and Therapy Evaluation Units (VTEUs) and the CIVICs program have injected substantial funding into the development of next-generation diagnostic tools and flu surveillance systems.
Business Opportunity
The shift toward decentralized testing and the growing availability of portable, user-friendly diagnostic kits present major growth opportunities for market participants. Manufacturers are increasingly focusing on delivering cost-effective molecular solutions suitable for resource-constrained settings, including emerging markets.
At the same time, the increasing demand for diagnostics in outpatient clinics, urgent care centers, and pharmacies highlights the need for scalable, easy-to-use platforms that require minimal technical expertise. This trend is opening doors for innovation in home-based and self-administered flu testing solutions.
Regional Analysis
North America remains the largest regional market, with the U.S. accounting for a dominant share due to the high prevalence of influenza, robust healthcare infrastructure, and the strong presence of diagnostic companies. The country continues to invest in advanced testing technologies, supporting rapid product development and commercialization.
Germany leads the European market owing to a combination of government support, presence of diagnostic manufacturers, and high awareness around influenza prevention and early detection. New kit launches and strategic collaborations among key players are driving innovation in the country.
In East Asia, Japan emerges as a key market, supported by a technologically advanced healthcare system, rising incidence of flu infections, and a growing geriatric population. Regulatory support and favorable insurance policies further facilitate access to advanced diagnostics.
Key Growth Drivers
The competitive Analysis is marked by strategic mergers, acquisitions, and product expansions. Key players are focusing on strengthening their product offerings and entering untapped regional markets.
• Thermo Fisher Scientific has introduced user-friendly RT-PCR systems such as QuantStudio 3 and 5, enabling remote access and analysis.
• Quidel Corporation has expanded its portfolio with FDA-cleared rapid flu and COVID-19 combo tests.
• Roche’s acquisition of GenMark Diagnostics has bolstered its molecular diagnostics capabilities, enhancing its global presence.
Other major players include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux Inc., Danaher Corporation (Cepheid), GenMark Diagnostics, Luminex Corporation, Meridian Bioscience, Inc., and Hologic.
Market Segmentation
By Test Type:
• Molecular Diagnostic Tests
RT-PCR
LAMP
NASABA
• Traditional Diagnostic Tests
Rapid Influenza Detection Test
Serological Assays
Direct Fluorescent Antibody
Viral Culture
H1N1 Influenza A Virus Identification Kits
Immunoassay Kits
Immunofluorescence Antibody Assay
By Type of Flu:
• Type A Flu
• Type B Flu
• Type C Flu
By End User:
• Hospitals
• Diagnostic Laboratories
• Research & Academic Institutes
• Contract Research Organizations (CROs)
By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Oceania
• Middle East & Africa
Please note: Delivery Timelines - 5 working days.
Table of Contents
248 Pages
- 1. Executive Summary
- 1.1. Global Influenza Diagnostics Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2025
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Influenza Diagnostics Market Outlook, 2019-2032
- 3.1. Global Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
- 3.1.1. Key Highlights
- 3.1.1.1. Molecular Diagnostic Test
- 3.1.1.1.1. RT-PCR
- 3.1.1.1.2. LAMP
- 3.1.1.1.3. NASABA
- 3.1.1.2. Traditional Diagnostic Test
- 3.1.1.2.1. Rapid Influenza Detection Test
- 3.1.1.2.2. Serological Assays
- 3.1.1.2.3. Direct Fluorescent Antibody
- 3.1.1.2.4. Viral Culture
- 3.1.1.2.5. H1N1 Influenza A Virus Identification Kits
- 3.1.1.2.6. Immunoassay Kits
- 3.1.1.2.7. Immunofluorescence Antibody Assay
- 3.2. Global Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
- 3.2.1. Key Highlights
- 3.2.1.1. Type A Flu
- 3.2.1.2. Type B Flu
- 3.2.1.3. Type C Flu
- 3.3. Global Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 3.3.1. Key Highlights
- 3.3.1.1. Hospitals
- 3.3.1.2. Diagnostic Laboratories
- 3.3.1.3. Research & Academic Institute
- 3.3.1.4. Contract Research Organization (CRO’s)
- 3.4. Global Influenza Diagnostics Market Outlook, by Region, Value (US$ Bn), 2019-2032
- 3.4.1. Key Highlights
- 3.4.1.1. North America
- 3.4.1.2. Europe
- 3.4.1.3. Asia Pacific
- 3.4.1.4. Latin America
- 3.4.1.5. Middle East & Africa
- 4. North America Influenza Diagnostics Market Outlook, 2019-2032
- 4.1. North America Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
- 4.1.1. Key Highlights
- 4.1.1.1. Molecular Diagnostic Test
- 4.1.1.1.1. RT-PCR
- 4.1.1.1.2. LAMP
- 4.1.1.1.3. NASABA
- 4.1.1.2. Traditional Diagnostic Test
- 4.1.1.2.1. Rapid Influenza Detection Test
- 4.1.1.2.2. Serological Assays
- 4.1.1.2.3. Direct Fluorescent Antibody
- 4.1.1.2.4. Viral Culture
- 4.1.1.2.5. H1N1 Influenza A Virus Identification Kits
- 4.1.1.2.6. Immunoassay Kits
- 4.1.1.2.7. Immunofluorescence Antibody Assay
- 4.2. North America Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
- 4.2.1. Key Highlights
- 4.2.1.1. Type A Flu
- 4.2.1.2. Type B Flu
- 4.2.1.3. Type C Flu
- 4.3. North America Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 4.3.1. Key Highlights
- 4.3.1.1. Hospitals
- 4.3.1.2. Diagnostic Laboratories
- 4.3.1.3. Research & Academic Institute
- 4.3.1.4. Contract Research Organization (CRO’s)
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
- 4.4. North America Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 4.4.1. Key Highlights
- 4.4.1.1. U.S. Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 4.4.1.2. U.S. Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 4.4.1.3. U.S. Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 4.4.1.4. Canada Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 4.4.1.5. Canada Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 4.4.1.6. Canada Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Influenza Diagnostics Market Outlook, 2019-2032
- 5.1. Europe Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
- 5.1.1. Key Highlights
- 5.1.1.1. Molecular Diagnostic Test
- 5.1.1.1.1. RT-PCR
- 5.1.1.1.2. LAMP
- 5.1.1.1.3. NASABA
- 5.1.1.2. Traditional Diagnostic Test
- 5.1.1.2.1. Rapid Influenza Detection Test
- 5.1.1.2.2. Serological Assays
- 5.1.1.2.3. Direct Fluorescent Antibody
- 5.1.1.2.4. Viral Culture
- 5.1.1.2.5. H1N1 Influenza A Virus Identification Kits
- 5.1.1.2.6. Immunoassay Kits
- 5.1.1.2.7. Immunofluorescence Antibody Assay
- 5.2. Europe Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
- 5.2.1. Key Highlights
- 5.2.1.1. Type A Flu
- 5.2.1.2. Type B Flu
- 5.2.1.3. Type C Flu
- 5.3. Europe Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 5.3.1. Key Highlights
- 5.3.1.1. Hospitals
- 5.3.1.2. Diagnostic Laboratories
- 5.3.1.3. Research & Academic Institute
- 5.3.1.4. Contract Research Organization (CRO’s)
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
- 5.4. Europe Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 5.4.1. Key Highlights
- 5.4.1.1. Germany Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 5.4.1.2. Germany Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 5.4.1.3. Germany Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 5.4.1.4. U.K. Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 5.4.1.5. U.K. Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 5.4.1.6. U.K. Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 5.4.1.7. France Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 5.4.1.8. France Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 5.4.1.9. France Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 5.4.1.10. Italy Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 5.4.1.11. Italy Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 5.4.1.12. Italy Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 5.4.1.13. Turkey Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 5.4.1.14. Turkey Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 5.4.1.15. Turkey Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 5.4.1.16. Russia Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 5.4.1.17. Russia Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 5.4.1.18. Russia Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 5.4.1.19. Rest of Europe Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 5.4.1.20. Rest of Europe Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 5.4.1.21. Rest of Europe Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Influenza Diagnostics Market Outlook, 2019-2032
- 6.1. Asia Pacific Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
- 6.1.1. Key Highlights
- 6.1.1.1. Molecular Diagnostic Test
- 6.1.1.1.1. RT-PCR
- 6.1.1.1.2. LAMP
- 6.1.1.1.3. NASABA
- 6.1.1.2. Traditional Diagnostic Test
- 6.1.1.2.1. Rapid Influenza Detection Test
- 6.1.1.2.2. Serological Assays
- 6.1.1.2.3. Direct Fluorescent Antibody
- 6.1.1.2.4. Viral Culture
- 6.1.1.2.5. H1N1 Influenza A Virus Identification Kits
- 6.1.1.2.6. Immunoassay Kits
- 6.1.1.2.7. Immunofluorescence Antibody Assay
- 6.2. Asia Pacific Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
- 6.2.1. Key Highlights
- 6.2.1.1. Type A Flu
- 6.2.1.2. Type B Flu
- 6.2.1.3. Type C Flu
- 6.3. Asia Pacific Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 6.3.1. Key Highlights
- 6.3.1.1. Hospitals
- 6.3.1.2. Diagnostic Laboratories
- 6.3.1.3. Research & Academic Institute
- 6.3.1.4. Contract Research Organization (CRO’s)
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
- 6.4. Asia Pacific Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 6.4.1. Key Highlights
- 6.4.1.1. China Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 6.4.1.2. China Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 6.4.1.3. China Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 6.4.1.4. Japan Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 6.4.1.5. Japan Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 6.4.1.6. Japan Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 6.4.1.7. South Korea Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 6.4.1.8. South Korea Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 6.4.1.9. South Korea Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 6.4.1.10. India Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 6.4.1.11. India Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 6.4.1.12. India Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 6.4.1.13. Southeast Asia Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 6.4.1.14. Southeast Asia Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 6.4.1.15. Southeast Asia Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 6.4.1.16. Rest of Asia Pacific Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 6.4.1.17. Rest of Asia Pacific Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 6.4.1.18. Rest of Asia Pacific Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Influenza Diagnostics Market Outlook, 2019-2032
- 7.1. Latin America Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
- 7.1.1. Key Highlights
- 7.1.1.1. Molecular Diagnostic Test
- 7.1.1.1.1. RT-PCR
- 7.1.1.1.2. LAMP
- 7.1.1.1.3. NASABA
- 7.1.1.2. Traditional Diagnostic Test
- 7.1.1.2.1. Rapid Influenza Detection Test
- 7.1.1.2.2. Serological Assays
- 7.1.1.2.3. Direct Fluorescent Antibody
- 7.1.1.2.4. Viral Culture
- 7.1.1.2.5. H1N1 Influenza A Virus Identification Kits
- 7.1.1.2.6. Immunoassay Kits
- 7.1.1.2.7. Immunofluorescence Antibody Assay
- 7.2. Latin America Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
- 7.2.1.1. Type A Flu
- 7.2.1.2. Type B Flu
- 7.2.1.3. Type C Flu
- 7.3. Latin America Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 7.3.1. Key Highlights
- 7.3.1.1. Hospitals
- 7.3.1.2. Diagnostic Laboratories
- 7.3.1.3. Research & Academic Institute
- 7.3.1.4. Contract Research Organization (CRO’s)
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
- 7.4. Latin America Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 7.4.1. Key Highlights
- 7.4.1.1. Brazil Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 7.4.1.2. Brazil Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 7.4.1.3. Brazil Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 7.4.1.4. Mexico Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 7.4.1.5. Mexico Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 7.4.1.6. Mexico Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 7.4.1.7. Argentina Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 7.4.1.8. Argentina Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 7.4.1.9. Argentina Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 7.4.1.10. Rest of Latin America Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 7.4.1.11. Rest of Latin America Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 7.4.1.12. Rest of Latin America Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Influenza Diagnostics Market Outlook, 2019-2032
- 8.1. Middle East & Africa Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
- 8.1.1. Key Highlights
- 8.1.1.1. Molecular Diagnostic Test
- 8.1.1.1.1. RT-PCR
- 8.1.1.1.2. LAMP
- 8.1.1.1.3. NASABA
- 8.1.1.2. Traditional Diagnostic Test
- 8.1.1.2.1. Rapid Influenza Detection Test
- 8.1.1.2.2. Serological Assays
- 8.1.1.2.3. Direct Fluorescent Antibody
- 8.1.1.2.4. Viral Culture
- 8.1.1.2.5. H1N1 Influenza A Virus Identification Kits
- 8.1.1.2.6. Immunoassay Kits
- 8.1.1.2.7. Immunofluorescence Antibody Assay
- 8.2. Middle East & Africa Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
- 8.2.1. Key Highlights
- 8.2.1.1. Type A Flu
- 8.2.1.2. Type B Flu
- 8.2.1.3. Type C Flu
- 8.3. Middle East & Africa Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 8.3.1. Key Highlights
- 8.3.1.1. Hospitals
- 8.3.1.2. Diagnostic Laboratories
- 8.3.1.3. Research & Academic Institute
- 8.3.1.4. Contract Research Organization (CRO’s)
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
- 8.4. Middle East & Africa Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 8.4.1. Key Highlights
- 8.4.1.1. GCC Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 8.4.1.2. GCC Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 8.4.1.3. GCC Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 8.4.1.4. South Africa Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 8.4.1.5. South Africa Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 8.4.1.6. South Africa Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 8.4.1.7. Egypt Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 8.4.1.8. Egypt Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 8.4.1.9. Egypt Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 8.4.1.10. Nigeria Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 8.4.1.11. Nigeria Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 8.4.1.12. Nigeria Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 8.4.1.13. Rest of Middle East & Africa Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
- 8.4.1.14. Rest of Middle East & Africa Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
- 8.4.1.15. Rest of Middle East & Africa Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. By Segment 3 vs by Type of Flu Heat map
- 9.2. Manufacturer vs by Type of Flu Heatmap
- 9.3. Company Market Share Analysis, 2025
- 9.4. Competitive Dashboard
- 9.5. Company Profiles
- 9.5.1. Abbott Laboratories
- 9.5.1.1. Company Overview
- 9.5.1.2. Product Portfolio
- 9.5.1.3. Financial Overview
- 9.5.1.4. Business Strategies and Development
- 9.5.2. Endress+Hauser (Analytik Jena AG)
- 9.5.2.1. Company Overview
- 9.5.2.2. Product Portfolio
- 9.5.2.3. Financial Overview
- 9.5.2.4. Business Strategies and Development
- 9.5.3. Becton, Dickinson and Company
- 9.5.3.1. Company Overview
- 9.5.3.2. Product Portfolio
- 9.5.3.3. Financial Overview
- 9.5.3.4. Business Strategies and Development
- 9.5.4. Biocartis
- 9.5.4.1. Company Overview
- 9.5.4.2. Product Portfolio
- 9.5.4.3. Financial Overview
- 9.5.4.4. Business Strategies and Development
- 9.5.5. bioMérieux Inc
- 9.5.5.1. Company Overview
- 9.5.5.2. Product Portfolio
- 9.5.5.3. Financial Overview
- 9.5.5.4. Business Strategies and Development
- 9.5.6. Danaher Corporation (Cepheid)
- 9.5.6.1. Company Overview
- 9.5.6.2. Product Portfolio
- 9.5.6.3. Financial Overview
- 9.5.6.4. Business Strategies and Development
- 9.5.7. F. Hoffmann-La Roche Ltd
- 9.5.7.1. Company Overview
- 9.5.7.2. Product Portfolio
- 9.5.7.3. Financial Overview
- 9.5.7.4. Business Strategies and Development
- 9.5.8. GenMark Diagnostics, Inc.
- 9.5.8.1. Company Overview
- 9.5.8.2. Product Portfolio
- 9.5.8.3. Financial Overview
- 9.5.8.4. Business Strategies and Development
- 9.5.9. Luminex Corporation
- 9.5.9.1. Company Overview
- 9.5.9.2. Product Portfolio
- 9.5.9.3. Financial Overview
- 9.5.9.4. Business Strategies and Development
- 9.5.10. Quidel Corporation
- 9.5.10.1. Company Overview
- 9.5.10.2. Product Portfolio
- 9.5.10.3. Financial Overview
- 9.5.10.4. Business Strategies and Development
- 9.5.11. Genesis Biosystems, Inc.
- 9.5.11.1. Company Overview
- 9.5.11.2. Product Portfolio
- 9.5.11.3. Financial Overview
- 9.5.11.4. Business Strategies and Development
- 9.5.12. Thermo Fisher Scientific Inc.
- 9.5.12.1. Company Overview
- 9.5.12.2. Product Portfolio
- 9.5.12.3. Financial Overview
- 9.5.12.4. Business Strategies and Development
- 9.5.13. Hologic
- 9.5.13.1. Company Overview
- 9.5.13.2. Product Portfolio
- 9.5.13.3. Financial Overview
- 9.5.13.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
